Alkermes Shares Surge Following Positive ADHD Drug Trial Results

Key Facts

1Alkermes shares surged following the announcement of positive clinical trial results for its ADHD treatment drug.

In a move reflecting the rapid developments within the biotechnology sector, Alkermes shares experienced a significant price jump following the announcement of positive clinical trial results. According to reports, these successful outcomes involve a drug candidate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This milestone is expected to increase the likelihood of future regulatory approval and commercial success for the company's treatment pipeline.

The positive market reaction underscores investor confidence in the company's ability to compete in the specialized pharmaceutical market, where successful clinical data typically drives significant upward price action. Based on the available facts, the achievement in these trials serves as a critical pillar for Alkermes' long-term growth strategy in the healthcare space.

Regarding stock performance, ALKS stood at $43.39 (at close September 18, 2026), having reached a day high of $46.53 during that session. Investors are now watching for further updates on regulatory filing timelines, while broader sector sentiment remains influenced by general economic indicators such as the recent NY Empire State Manufacturing Index reading of 7.6.